

Controlled Attenuation Parameter (CAP): a noninvasive hepatic steatosis based on transient elastography

Liver International

32, 902-910

DOI: [10.1111/j.1478-3231.2012.02781.x](https://doi.org/10.1111/j.1478-3231.2012.02781.x)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Obstructive Sleep Apnea and Non-Alcoholic Fatty Liver Disease: Is the Liver Another Target?. <i>Frontiers in Neurology</i> , 2012, 3, 149.	1.1	61
2	Management of Nonalcoholic Fatty Liver Disease. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 608-16.	3.8	18
3	Controlled attenuation parameter (<sc>CAP</sc>): a new device for fast evaluation of liver fat?. <i>Liver International</i> , 2012, 32, 875-877.	1.9	24
4	Non-Invasive Evaluation of Liver Steatosis, Fibrosis and Cirrhosis in Hepatitis C Virus Infected Patients Using Unidimensional Transient Elastography (Fibroscan®). , 0, , .		3
5	The Fatty Liver Index has limited utility for the detection and quantification of hepatic steatosis in obese patients. <i>Hepatology International</i> , 2013, 7, 592-599.	1.9	19
6	Ultrasonographic Quantification of Hepatic Renal Echogenicity Difference in Hepatic Steatosis Diagnosis. <i>Digestive Diseases and Sciences</i> , 2013, 58, 2993-3000.	1.1	20
7	Noninvasive evaluation of NAFLD. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2013, 10, 666-675.	8.2	238
8	Utility of controlled attenuation parameter measurement for assessing liver steatosis in <sc>J</sc>apanese patients with chronic liver diseases. <i>Hepatology Research</i> , 2013, 43, 1182-1189.	1.8	55
9	Controlled attenuation parameter for non-invasive assessment of hepatic steatosis: Does etiology affect performance?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 1194-1201.	1.4	87
10	Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal. <i>Journal of Hepatology</i> , 2013, 58, 1007-1019.	1.8	332
11	The effect of a glucagon-like peptide-1 receptor agonist on glucose tolerance in women with previous gestational diabetes mellitus: protocol for an investigator-initiated, randomised, placebo-controlled, double-blinded, parallel intervention trial. <i>BMJ Open</i> , 2013, 3, e003834.	0.8	9
12	Utility of controlled attenuation parameter measurement for assessing liver steatosis in <sc>J</sc>apanese patients with chronic liver diseases. <i>Hepatology Research</i> , 2013, 43, 1125-1126.	1.8	3
13	Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification. <i>Journal of Clinical Pathology</i> , 2013, 66, 1033-1045.	1.0	70
14	Influence of heterogeneities on ultrasound attenuation for liver steatosis evaluation (CAP™): Relevance of a liver guidance tool. , 2013, , .		2
15	Clinical and Virological Characteristics of Chronic Hepatitis B Patients with Hepatic Steatosis. <i>International Journal of Medical Sciences</i> , 2013, 10, 641-646.	1.1	25
16	Liver elastography, comments on EFSUMB elastography guidelines 2013. <i>World Journal of Gastroenterology</i> , 2013, 19, 6329.	1.4	51
17	Non-Invasive Assessment of Hepatic Steatosis in Patients with NAFLD Using Controlled Attenuation Parameter and 1H-MR Spectroscopy. <i>PLoS ONE</i> , 2014, 9, e91987.	1.1	130
18	Invasive and non-invasive diagnosis of cirrhosis and portal hypertension. <i>World Journal of Gastroenterology</i> , 2014, 20, 4300.	1.4	98

#	ARTICLE	IF	CITATIONS
19	Controlled attenuation parameter for non-invasive assessment of hepatic steatosis in Chinese patients. <i>World Journal of Gastroenterology</i> , 2014, 20, 4702.	1.4	92
20	Clinical differences between alcoholic liver disease and nonalcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2014, 20, 8393.	1.4	118
21	A comparison of FibroMeter [®] , [‡] NAFLD Score, NAFLD fibrosis score, and transient elastography as noninvasive diagnostic tools for hepatic fibrosis in patients with biopsy-proven non-alcoholic fatty liver disease. <i>Scandinavian Journal of Gastroenterology</i> , 2014, 49, 1343-1348.	0.6	43
22	Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1470-1476.	1.4	148
23	Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 1209-1222.	1.9	328
24	Prevalence and factors associated with liver steatosis as measured by transient elastography with controlled attenuation parameter in HIV-infected patients. <i>Aids</i> , 2014, 28, 1279-1287.	1.0	59
25	Interobserver reproducibility of the controlled attenuation parameter (CAP) for quantifying liver steatosis. <i>Hepatology International</i> , 2014, 8, 576-581.	1.9	32
26	Controlled attenuation parameter (<scp>CAP</scp>) for detection of hepatic steatosis in patients with chronic liver diseases: a prospective study of a native Korean population. <i>Liver International</i> , 2014, 34, 102-109.	1.9	143
27	Getting closer to a point-of-care diagnostic assessment in patients with chronic liver disease: Controlled attenuation parameter for steatosis. <i>Journal of Hepatology</i> , 2014, 60, 910-912.	1.8	35
29	New and Improved Imaging Modalities for NAFLD. <i>Current Hepatology Reports</i> , 2014, 13, 88-96.	0.4	1
30	Republished: Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification. <i>Postgraduate Medical Journal</i> , 2014, 90, 254-266.	0.9	12
31	Controlled attenuation parameter (CAP) for the diagnosis of steatosis: A prospective study of 5323 examinations. <i>Journal of Hepatology</i> , 2014, 60, 1026-1031.	1.8	318
32	Quantitative Assessment of Steatosis in Liver Tissue Using Controlled Attenuation Parameter. <i>Journal of Medical Ultrasound</i> , 2014, 22, 131-132.	0.2	0
33	Controlled attenuation parameter for the detection of steatosis severity in chronic liver disease: A meta-analysis of diagnostic accuracy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1149-1158.	1.4	132
34	Detection of hepatic steatosis using the controlled attenuation parameter: a comparative study with liver biopsy. <i>Scandinavian Journal of Gastroenterology</i> , 2014, 49, 611-616.	0.6	31
35	Ultrasound in chronic liver disease. <i>Insights Into Imaging</i> , 2014, 5, 441-455.	1.6	88
36	Controlled Attenuation Parameter and Liver Stiffness Measurements for Steatosis Assessment in the Liver Transplant of Brain Dead Donors. <i>Transplantation</i> , 2015, 99, 1619-1624.	0.5	24
37	Impact of skin capsular distance on the performance of controlled attenuation parameter in patients with chronic liver disease. <i>Liver International</i> , 2015, 35, 2392-2400.	1.9	71

#	ARTICLE	IF	CITATIONS
38	Nonalcoholic fatty liver disease. <i>Nature Reviews Disease Primers</i> , 2015, 1, 15080.	18.1	612
39	Impact of genetic polymorphisms associated with nonalcoholic fatty liver disease on HIV-infected individuals. <i>Aids</i> , 2015, 29, 1927-1935.	1.0	19
40	Estimating steatosis and fibrosis: Comparison of acoustic structure quantification with established techniques. <i>World Journal of Gastroenterology</i> , 2015, 21, 4894.	1.4	37
41	Associations of Erythrocyte Fatty Acids in the De Novo Lipogenesis Pathway with Proxies of Liver Fat Accumulation in the EPIC-Potsdam Study. <i>PLoS ONE</i> , 2015, 10, e0127368.	1.1	25
42	Transient Elastography-Based Liver Profiles in a Hospital-Based Pediatric Population in Japan. <i>PLoS ONE</i> , 2015, 10, e0137239.	1.1	54
43	Diagnostic performance of controlled attenuation parameter for predicting steatosis grade in chronic hepatitis B. <i>Annals of Hepatology</i> , 2015, 14, 826-836.	0.6	18
44	Noninvasive assessment of alcoholic liver disease using unidimensional transient elastography (Fibroscan [®]). <i>World Journal of Gastroenterology</i> , 2015, 21, 11914.	1.4	18
45	Non-invasive diagnostic approach to non-alcoholic fatty liver disease: current evidence and future perspectives. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 1039-1053.	1.4	13
46	Role of ultrasound in the diagnosis and treatment of nonalcoholic fatty liver disease and its complications. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 603-627.	1.4	102
47	Nonalcoholic fatty liver disease: Noninvasive methods of diagnosing hepatic steatosis. <i>Saudi Journal of Gastroenterology</i> , 2015, 21, 64.	0.5	26
48	Fat and Fiber: How the Controlled Attenuation Parameter Complements Noninvasive Assessment of Liver Fibrosis. <i>Digestive Diseases and Sciences</i> , 2015, 60, 9-12.	1.1	12
49	Correlation of the controlled attenuation parameter with indices of liver steatosis in overweight or obese individuals. <i>European Journal of Gastroenterology and Hepatology</i> , 2015, 27, 305-312.	0.8	10
50	New reliability criteria for transient elastography increase the number of accurate measurements for screening of cirrhosis and portal hypertension. <i>Liver International</i> , 2015, 35, 381-390.	1.9	111
52	Noninvasive Diagnosis of Nonalcoholic Fatty Liver Disease and Quantification of Liver Fat Using a New Quantitative Ultrasound Technique. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1337-1345.e6.	2.4	200
53	Noninvasive characterization of graft steatosis after liver transplantation. <i>Scandinavian Journal of Gastroenterology</i> , 2015, 50, 224-232.	0.6	28
54	Controlled Attenuation Parameter for Noninvasive Assessment of Hepatic Steatosis Using Fibroscan [®] : Validation in Chronic Hepatitis B. <i>Digestive Diseases and Sciences</i> , 2015, 60, 243-251.	1.1	35
55	The Relationship between Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease Measured by Controlled Attenuation Parameter. <i>Yonsei Medical Journal</i> , 2016, 57, 885.	0.9	31
56	Transient elastography (FibroScan [®]) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand?. <i>World Journal of Gastroenterology</i> , 2016, 22, 7236.	1.4	193

#	ARTICLE	IF	CITATIONS
57	Discrimination of Nonalcoholic Steatohepatitis Using Transient Elastography in Patients with Nonalcoholic Fatty Liver Disease. <i>PLoS ONE</i> , 2016, 11, e0157358.	1.1	62
58	Controlled attenuation parameter for the diagnosis of steatosis in nonalcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 848-855.	1.4	151
59	Controlled attenuation parameter is correlated with actual hepatic fat content in patients with nonalcoholic fatty liver disease with none to mild obesity and liver fibrosis. <i>Hepatology Research</i> , 2016, 46, 1019-1027.	1.8	35
60	Hypertension and nonalcoholic fatty liver disease proven by transient elastography. <i>Hepatology Research</i> , 2016, 46, 1304-1310.	1.8	30
61	Changes in liver steatosis evaluated by transient elastography with the controlled attenuation parameter in HIV-infected patients. <i>HIV Medicine</i> , 2016, 17, 766-773.	1.0	23
63	Time Harmonic Elastography Reveals Sensitivity of Liver Stiffness to Water Ingestion. <i>Ultrasound in Medicine and Biology</i> , 2016, 42, 1289-1294.	0.7	31
64	Noninvasive Markers of Fibrosis and Inflammation in Nonalcoholic Fatty Liver Disease. <i>Current Hepatology Reports</i> , 2016, 15, 86-95.	0.4	23
65	Non-alcoholic fatty liver disease in 2016. <i>British Medical Bulletin</i> , 2016, 119, 143-156.	2.7	61
66	The clinical value of controlled attenuation parameter for the noninvasive assessment of liver steatosis. <i>Liver International</i> , 2016, 36, 1860-1866.	1.9	19
67	Prevalence of hepatic steatosis in apparently healthy medical students: a transient elastography study on the basis of a controlled attenuation parameter. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 1264-1267.	0.8	18
68	MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: Clinical trials to clinical practice. <i>Journal of Hepatology</i> , 2016, 65, 1006-1016.	1.8	275
69	Controlled attenuation parameter for the detection of hepatic steatosis in patients with chronic hepatitis B. <i>Infectious Diseases</i> , 2016, 48, 670-675.	1.4	7
70	Biopsy and Noninvasive Methods to Assess Progression of Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2016, 150, 1811-1822.e4.	0.6	93
71	Liver Steatosis Assessed by Controlled Attenuation Parameter (CAP) Measured with the XL Probe of the FibroScan: A Pilot Study Assessing Diagnostic Accuracy. <i>Ultrasound in Medicine and Biology</i> , 2016, 42, 92-103.	0.7	115
72	Noninvasive Prediction of Erosive Esophagitis Using a Controlled Attenuation Parameter (CAP)-Based Risk Estimation Model. <i>Digestive Diseases and Sciences</i> , 2016, 61, 507-516.	1.1	3
73	Controlled attenuation parameter using the FibroScan® XL probe for quantification of hepatic steatosis for nonalcoholic fatty liver disease in an Asian population. <i>United European Gastroenterology Journal</i> , 2017, 5, 76-85.	1.6	67
74	Validity criteria for the diagnosis of fatty liver by M probe-based controlled attenuation parameter. <i>Journal of Hepatology</i> , 2017, 67, 577-584.	1.8	110
75	Prevalence and Predictors of Significant Fibrosis Among Subjects with Transient Elastography-Defined Nonalcoholic Fatty Liver Disease. <i>Digestive Diseases and Sciences</i> , 2017, 62, 2150-2158.	1.1	18

#	ARTICLE	IF	CITATIONS
76	Controlled attenuation parameter for diagnosing steatosis in bariatric surgery candidates with suspected nonalcoholic fatty liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 1022-1030.	0.8	28
77	A comparison of hepatic steatosis index, controlled attenuation parameter and ultrasound as noninvasive diagnostic tools for steatosis in chronic hepatitis B. <i>Digestive and Liver Disease</i> , 2017, 49, 910-917.	0.4	45
78	Clinical usefulness of controlled attenuation parameter to screen hepatic steatosis for potential donor of living donor liver transplant. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 805-810.	0.8	26
79	Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. <i>Journal of Hepatology</i> , 2017, 66, 1022-1030.	1.8	734
80	Clinical characteristics of antimitochondrial antibody-positive patients at a safety net health care system in Arizona. <i>BMJ Open Gastroenterology</i> , 2017, 4, e000158.	1.1	3
81	Metabonomics screening of serum identifies pyroglutamate as a diagnostic biomarker for nonalcoholic steatohepatitis. <i>Clinica Chimica Acta</i> , 2017, 473, 89-95.	0.5	38
82	The role of bariatric surgery in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2017, 11, 797-811.	1.4	24
83	Fat Quantification in the Abdomen. <i>Topics in Magnetic Resonance Imaging</i> , 2017, 26, 221-227.	0.7	22
84	Potential impact of screening for fatty liver disease by transient elastography with liver stiffness and controlled attenuation parameter measurements: a pilot study. <i>Zeitschrift Fur Gastroenterologie</i> , 2017, 55, 754-760.	0.2	0
85	Non-invasive diagnosis of hepatic steatosis. <i>Hepatology International</i> , 2017, 11, 70-78.	1.9	101
86	Magnetic Resonance Elastography vs Transient Elastography in Detection of Fibrosis and Noninvasive Measurement of Steatosis in Patients With Biopsy-Proven Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2017, 152, 598-607.e2.	0.6	510
87	Transient elastography for the diagnosis of liver fibrosis: a systematic review of economic evaluations. <i>Liver International</i> , 2017, 37, 851-861.	1.9	28
88	Nonalcoholic fatty liver disease: one entity, multiple impacts on liver health. <i>Cell Biology and Toxicology</i> , 2017, 33, 5-14.	2.4	11
90	Diagnostic Accuracy of Controlled Attenuation Parameter for Detecting Hepatic Steatosis in Patients with Chronic Liver Disease. <i>GE Portuguese Journal of Gastroenterology</i> , 2017, 24, 161-168.	0.3	15
91	Changes in Liver Steatosis After Switching From Efavirenz to Raltegravir Among Human Immunodeficiency Virus-Infected Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Infectious Diseases</i> , 2017, 65, 1012-1019.	2.9	42
92	Imaging-Based Assessment of Steatosis, Inflammation and Fibrosis in NAFLD. <i>Current Hepatology Reports</i> , 2017, 16, 298-307.	0.4	9
93	Development of coaxial ultrasonic probe for fatty liver diagnostic system using ultrasonic velocity change. <i>Japanese Journal of Applied Physics</i> , 2017, 56, 07JF24.	0.8	3
94	Nonalcoholic fatty liver disease: Evolving paradigms. <i>World Journal of Gastroenterology</i> , 2017, 23, 6571-6592.	1.4	138

#	ARTICLE	IF	CITATIONS
95	Genetic polymorphisms associated with fatty liver disease and fibrosis in HIV positive patients receiving combined antiretroviral therapy (cART). PLoS ONE, 2017, 12, e0178685.	1.1	13
96	Imaging evaluation of non-alcoholic fatty liver disease: focused on quantification. Clinical and Molecular Hepatology, 2017, 23, 290-301.	4.5	105
97	Protein and vitamin B6 intake are associated with liver steatosis assessed by transient elastography, especially in obese individuals. Clinical and Molecular Hepatology, 2017, 23, 249-259.	4.5	20
98	Can the same controlled attenuation parameter cut-offs be used for M and XL probes for diagnosing hepatic steatosis?. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 1787-1794.	1.4	40
99	[11C]acetate PET as a tool for diagnosis of liver steatosis. Abdominal Radiology, 2018, 43, 2963-2969.	1.0	3
100	Repeatability and Reproducibility of the Ultrasonic Attenuation Coefficient and Backscatter Coefficient Measured in the Right Lobe of the Liver in Adults With Known or Suspected Nonalcoholic Fatty Liver Disease. Journal of Ultrasound in Medicine, 2018, 37, 1913-1927.	0.8	43
101	Clinical Predictors of Liver Fibrosis in Patients With Chronic Hepatitis B Virus Infection From Children to Adults. Journal of Infectious Diseases, 2018, 217, 1408-1416.	1.9	25
102	Hepatic Steatosis and its Effects on Fibrosis in Patients With Chronic Hepatitis B Virus Infection. Clinical Gastroenterology and Hepatology, 2018, 16, 491-494.	2.4	4
103	Discordance in steatosis classification between liver biopsy and transient elastography for high controlled attenuation parameter (CAP) values. Zeitschrift Fur Gastroenterologie, 2018, 56, 36-42.	0.2	2
104	Clinical implications of controlled attenuation parameter in a health check-up cohort. Liver International, 2018, 38, 915-923.	1.9	15
105	MR Spectroscopy-derived Proton Density Fat Fraction Is Superior to Controlled Attenuation Parameter for Detecting and Grading Hepatic Steatosis. Radiology, 2018, 286, 547-556.	3.6	79
106	Serial changes in liver stiffness and controlled attenuation parameter following direct-acting antiviral therapy against hepatitis C virus genotype 1b. Journal of Medical Virology, 2018, 90, 313-319.	2.5	51
107	Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Noninvasive Biomarkers and Transient Elastography. Clinics in Liver Disease, 2018, 22, 73-92.	1.0	73
108	Optimal cutoff value for assessing changes in intrahepatic fat amount by using the controlled attenuation parameter in a longitudinal setting. Medicine (United States), 2018, 97, e13636.	0.4	9
109	Improvement of a combined ultrasonic probe used in ultrasonic velocity-change method for evaluation of fat content. Japanese Journal of Applied Physics, 2018, 57, 07LF18.	0.8	5
110	Ultrasound Entropy Imaging of Nonalcoholic Fatty Liver Disease: Association with Metabolic Syndrome. Entropy, 2018, 20, 893.	1.1	23
111	Non-invasive Assessment of Liver Steatosis and Fibrosis Using Transient Elastography and Controlled Attenuation Parameter in type 2 Diabetes Patients. Acta Endocrinologica, 2018, 14, 394-400.	0.1	2
112	The Role of Radiologic Modalities in Diagnosing Nonalcoholic Steatohepatitis (NASH) and Fibrosis. Current Hepatology Reports, 2018, 17, 324-335.	0.4	8

#	ARTICLE	IF	CITATIONS
113	Relationship between Serum Cytokeratin-18, Control Attenuation Parameter, NAFLD Fibrosis Score, and Liver Steatosis in Nonalcoholic Fatty Liver Disease. <i>International Journal of Hepatology</i> , 2018, 2018, 1-9.	0.4	12
114	GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2018, 155, 1463-1473.e6.	0.6	238
115	Update on Pediatric Fatty Liver Disease. <i>Current Hepatology Reports</i> , 2018, 17, 361-366.	0.4	0
116	Quantitative Hepatic Fat Quantification in Non-alcoholic Fatty Liver Disease Using Ultrasound-Based Techniques: A Review of Literature and Their Diagnostic Performance. <i>Ultrasound in Medicine and Biology</i> , 2018, 44, 2461-2475.	0.7	80
117	Liver Ultrasound Elastography: An Update to the World Federation for Ultrasound in Medicine and Biology Guidelines and Recommendations. <i>Ultrasound in Medicine and Biology</i> , 2018, 44, 2419-2440.	0.7	357
118	Nonalcoholic fatty liver disease: current concepts, epidemiology and management strategies. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 1103-1115.	0.8	56
119	Diagnosis and Characterization of Non-Alcoholic Fatty Liver Disease. , 0, , .		4
120	Usefulness of controlled attenuation parameter for detecting increased arterial stiffness in general population. <i>Digestive and Liver Disease</i> , 2018, 50, 1062-1067.	0.4	9
121	Noninvasive Evaluation of Fibrosis and Steatosis in Nonalcoholic Fatty Liver Disease by Elastographic Methods. , 0, , .		2
122	The B-Mode Image-Guided Ultrasound Attenuation Parameter Accurately Detects Hepatic Steatosis in Chronic Liver Disease. <i>Ultrasound in Medicine and Biology</i> , 2018, 44, 2223-2232.	0.7	103
123	MEASUREMENT OF CONTROLLED ATTENUATION PARAMETER: A SURROGATE MARKER OF HEPATIC STEATOSIS IN PATIENTS OF NONALCOHOLIC FATTY LIVER DISEASE ON LIFESTYLE MODIFICATION - A PROSPECTIVE FOLLOW-UP STUDY. <i>Arquivos De Gastroenterologia</i> , 2018, 55, 7-13.	0.3	10
124	Return-to-health effect of modern combined antiretroviral therapy potentially predisposes HIV patients to hepatic steatosis. <i>Medicine (United States)</i> , 2018, 97, e0462.	0.4	29
125	Improvements of Liver MR Imaging Clinical Protocols to Simultaneously Quantify Steatosis and Iron Overload. <i>Irbm</i> , 2018, 39, 219-225.	3.7	3
126	Reader agreement and accuracy of ultrasound features for hepatic steatosis. <i>Abdominal Radiology</i> , 2019, 44, 54-64.	1.0	16
127	Transient elastography: should XL probe be used in all overweight patients?. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 1022-1026.	0.6	10
128	Transient liver elastography in normal pregnancy â€” a longitudinal cohort study. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 761-765.	0.6	26
129	Circulating levels of PRO-C3 reflect liver fibrosis and liver function in HIV positive patients receiving modern cART. <i>PLoS ONE</i> , 2019, 14, e0219526.	1.1	10
130	Editorial: effect of hepatic steatosis on liver stiffness in patients with chronic hepatitis Bâ€™authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 334-335.	1.9	1

#	ARTICLE	IF	CITATIONS
131	Usefulness of Transient Elastography for Non-Invasive Diagnosis of Liver Fibrosis in Pediatric Non-Alcoholic Steatohepatitis. <i>Journal of Korean Medical Science</i> , 2019, 34, e165.	1.1	16
132	Quantification of Liver Fat in NAFLD: Available Modalities and Clinical Significance. <i>Current Hepatology Reports</i> , 2019, 18, 492-502.	0.4	6
133	A review of the use of transient elastography in the assessment of fibrosis and steatosis in the post-liver transplant patient. <i>Clinical Transplantation</i> , 2019, 33, e13700.	0.8	22
134	Elastodiagnosis of diseases: A review. <i>Extreme Mechanics Letters</i> , 2019, 27, 102-123.	2.0	19
135	Effect of diet-induced weight loss on cytokeratin-18 levels in overweight and obese patients with liver fibrosis. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2019, 13, 989-994.	1.8	7
136	Adaptation of controlled attenuation parameter (CAP) measurement depth in morbidly obese patients addressed for bariatric surgery. <i>PLoS ONE</i> , 2019, 14, e0217093.	1.1	9
137	Considerations of Ultrasound Scanning Approaches in Non-alcoholic Fatty Liver Disease Assessment through Acoustic Structure Quantification. <i>Ultrasound in Medicine and Biology</i> , 2019, 45, 1955-1969.	0.7	17
138	Low-molecular-weight fucoidan and high-stability fucoxanthin decrease serum alanine transaminase in patients with nonalcoholic fatty liver disease: A double-blind, randomized controlled trial. <i>Advances in Digestive Medicine</i> , 2019, 6, 116-122.	0.1	4
139	The Paradoxical Protective Effect of Liver Steatosis on Severity and Functional Outcome of Ischemic Stroke. <i>Frontiers in Neurology</i> , 2019, 10, 375.	1.1	9
140	Non-Invasive Assessment Method Using Thoracic-Abdominal Profile Image Acquisition and Mathematical Modeling with Bezier Curves. <i>Journal of Clinical Medicine</i> , 2019, 8, 65.	1.0	3
141	Steatosis Rates by Liver Biopsy and Transient Elastography With Controlled Attenuation Parameter in Clinical Experience of Hepatitis C Virus (HCV) and Human Immunodeficiency Virus/HCV Coinfection in a Large US Hepatitis Clinic. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz099.	0.4	14
142	Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2019, 156, 1717-1730.	0.6	777
143	Weight Gain and Liver Steatosis in Patients with Inflammatory Bowel Diseases. <i>Nutrients</i> , 2019, 11, 303.	1.7	10
144	<p>>The Circulating Micro-RNAs (miR-122, miR-34a and miR-99a) as Predictive Biomarkers for Non-Alcoholic Fatty Liver Diseases</p></p>. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2019, Volume 12, 2715-2723.	1.1	18
145	The clinical usefulness of elastography in the evaluation of nonalcoholic fatty liver disease patients: A biopsy-controlled study. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 1010-1016.	0.8	9
146	Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 285-292.	2.2	243
147	Controlled attenuation parameter: A measure of hepatic steatosis in patients with cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2019, 18, 280-285.	0.3	8
148	Clinical significance of hepatic steatosis according to coronary plaque morphology: assessment using controlled attenuation parameter. <i>Journal of Gastroenterology</i> , 2019, 54, 271-280.	2.3	21

#	ARTICLE	IF	CITATIONS
149	Controlled Attenuation Parameter for Assessment of Hepatic Steatosis in Indian Patients. <i>Journal of Clinical and Experimental Hepatology</i> , 2019, 9, 13-21.	0.4	24
150	Novel predictive models using serum ceruloplasmin levels for hepatic steatosis in patients with chronic hepatitis B infection. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2020, 44, 57-65.	0.7	4
151	Hepatic FATP5 expression is associated with histological progression and loss of hepatic fat in NAFLD patients. <i>Journal of Gastroenterology</i> , 2020, 55, 227-243.	2.3	29
152	Derivation and Internal Validation of a Clinical Prediction Tool to Predict Nonalcoholic Fatty Liver Disease in Patients With Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1917-1925.	0.9	11
153	One Year's Treatment with the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Decreases Hepatic Fat Content in Women with Nonalcoholic Fatty Liver Disease and Prior Gestational Diabetes Mellitus in a Randomized, Placebo-Controlled Trial. <i>Journal of Clinical Medicine</i> , 2020, 9, 3213.	1.0	14
154	Diagnostic Accuracy of FibroScan and Factors Affecting Measurements. <i>Diagnostics</i> , 2020, 10, 940.	1.3	44
155	Evaluating and minimizing batch effects in metabolomics. <i>Mass Spectrometry Reviews</i> , 2022, 41, 421-442.	2.8	42
156	Randomized Clinical Trial: Bergamot Citrus and Wild Cardoon Reduce Liver Steatosis and Body Weight in Non-diabetic Individuals Aged Over 50 Years. <i>Frontiers in Endocrinology</i> , 2020, 11, 494.	1.5	33
157	Higher cut-off values of non-invasive methods might be needed to detect moderate-to-severe steatosis in morbid obese patients: a pilot study. <i>Scientific Reports</i> , 2020, 10, 15007.	1.6	2
158	Plasma phospholipid dysregulation in patients with cystathionine-Î ² synthase deficiency. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020, 30, 2286-2295.	1.1	4
159	Liver steatosis is highly prevalent and is associated with metabolic risk factors and liver fibrosis in adult patients with type 1 Gaucher disease. <i>Liver International</i> , 2020, 40, 3061-3070.	1.9	13
160	Functional Microbial Responses to Alcohol Abstinence in Patients With Alcohol Use Disorder. <i>Frontiers in Physiology</i> , 2020, 11, 370.	1.3	11
161	LncPRYP4-3 serves as a novel diagnostic biomarker for dissecting subtypes of metabolic associated fatty liver disease by targeting RPS4Y2. <i>Clinical and Experimental Medicine</i> , 2020, 20, 587-600.	1.9	10
162	Computed tomography-based evaluation of segmental variation of liver density and its implications. <i>Indian Journal of Gastroenterology</i> , 2020, 39, 60-65.	0.7	1
163	Noninvasive Diagnosis of Nonalcoholic Fatty Liver Disease and Quantification of Liver Fat with Radiofrequency Ultrasound Data Using One-dimensional Convolutional Neural Networks. <i>Radiology</i> , 2020, 295, 342-350.	3.6	79
164	Transient elastography for assessment of fibrosis and steatosis of liver grafts from brain-death donors. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2020, 44, 155-161.	0.7	6
165	Assessment of Hepatic Steatosis in Nonalcoholic Fatty Liver Disease by Using Quantitative US. <i>Radiology</i> , 2020, 295, 106-113.	3.6	57
166	Noninvasive Diagnosis of NAFLD and NASH. <i>Cells</i> , 2020, 9, 1005.	1.8	145

#	ARTICLE	IF	CITATIONS
167	Diagnostic accuracy of FibroScan®AST score to identify non-alcoholic steatohepatitis with significant activity and fibrosis in Japanese patients with non-alcoholic fatty liver disease: Comparison between M and XL probes. <i>Hepatology Research</i> , 2020, 50, 831-839.	1.8	32
168	Diagnostic Accuracy of Controlled Attenuation Parameter Measured by Transient Elastography for the Non-invasive Assessment of Liver Steatosis: a Prospective Study. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 24, 35-42.	0.5	42
169	La utilidad cl�nica de la elastograf�a transitoria como una herramienta de imagenolog�a para evaluar el impacto a corto plazo de la gastrectom�a laparosc�pica en manga, en conjunto con par�metros cl�nicos y bioqu�micos e �ndices cl�nico-bioqu�micos en pacientes con enfermedad de h�gado graso no alcoh�lico: un estudio piloto egipcio. <i>Revista De Gastroenterolog�a De M�xico</i> , 2021, 86, 125-132.	0.4	0
170	Effects of anthropometric and metabolic parameters on transaminase levels and liver stiffness in patients with non-alcohol fatty liver disease. <i>Tropical Doctor</i> , 2021, 51, 185-189.	0.2	1
171	Liver complications of haemoglobin H disease in adults. <i>British Journal of Haematology</i> , 2021, 192, 171-178.	1.2	3
172	Usefulness of Controlled Attenuation Parameter and Liver Stiffness Measurement for the Identification of Extended-criteria Donors and Risk-assessment in Liver Transplantation. <i>Transplantation</i> , 2021, Publish Ahead of Print, .	0.5	4
173	Risk of hepatocellular carcinoma and fibrosis evolution in hepatitis C patients with severe fibrosis or cirrhosis treated with direct acting antiviral agents. <i>Acta Gastro-Enterologica Belgica</i> , 2021, 84, 25-32.	0.4	11
174	Analysis of liver steatosis analysis and controlled attenuation parameter for grading liver steatosis in patients with chronic hepatitis B. <i>Quantitative Imaging in Medicine and Surgery</i> , 2021, 11, 571-578.	1.1	5
175	Controlled Attenuation Parameter for Quantification of Steatosis: Which Cut-Offs to Use?. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2021, 2021, 1-7.	0.8	22
176	Clinical utility of transient elastography as an imaging tool to assess the short-term impact of laparoscopic sleeve gastrectomy, together with clinical and biochemical parameters and clinico-biochemical indices, on obese patients with nonalcoholic fatty liver disease: An Egyptian pilot study. <i>Revista De Gastroenterolog�a De M�xico (English Edition)</i> , 2021, 86, 125-132.	0.1	0
177	The prevalence of metabolic associated fatty liver detected by FibroScan® in women with gestational diabetes in a multiethnic population. <i>Diabetes Research and Clinical Practice</i> , 2021, 174, 108757.	1.1	3
178	Defining values for controlled attenuation parameter and liver stiffness in youth without liver disease. <i>Pediatric Research</i> , 2022, 91, 912-920.	1.1	5
179	Magnetic Resonance Spectroscopy of Hepatic Fat from Fundamental to Clinical Applications. <i>Diagnostics</i> , 2021, 11, 842.	1.3	16
180	Editorial for "Assessment of Imaging Modalities Against Liver Biopsy in Nonalcoholic Fatty Liver Disease: The Amsterdam <sc>NAFLD&NASH</sc> Cohort". <i>Journal of Magnetic Resonance Imaging</i> , 2021, 54, 1950-1951.	1.9	1
181	The Association between Vitamin D and Nonalcoholic Fatty Liver Disease Assessed by Controlled Attenuation Parameter. <i>Journal of Clinical Medicine</i> , 2021, 10, 2611.	1.0	9
182	Estimation of Liver Fat by FibroScan in Patients With Nonalcoholic Fatty Liver Disease. <i>Cureus</i> , 2021, 13, e16414.	0.2	1
183	KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 363-401.	4.5	152
184	Associations of Dietary Lipid-Soluble Micronutrients with Hepatic Steatosis among Adults in the United States. <i>Biomedicines</i> , 2021, 9, 1093.	1.4	2

#	ARTICLE	IF	CITATIONS
185	Quantitative assessment of fatty liver using ultrasound attenuation imaging. <i>Journal of Medical Ultrasonics</i> (2001), 2021, 48, 465-470.	0.6	9
186	Antenatal FibroScan [®] assessment for metabolic associated fatty liver in pregnant women at risk of gestational diabetes from a multiethnic population – a pilot study. <i>Internal Medicine Journal</i> , 2021, , .	0.5	0
187	Changes in liver steatosis in HIV-positive women are associated with the BMI, but not with biomarkers. <i>Cytokine</i> , 2021, 144, 155573.	1.4	5
188	The Association between Low Muscle Mass and Hepatic Steatosis in Asymptomatic Population in Korea. <i>Life</i> , 2021, 11, 848.	1.1	3
189	Noninvasive Estimation of Hepatic Steatosis by Controlled Attenuation Parameter in Living Donor Liver Transplant. <i>Experimental and Clinical Transplantation</i> , 2022, 20, 674-679.	0.2	1
190	Strategies to Diagnose Nonalcoholic Steatohepatitis: A Novel Approach to Take Advantage of Pharmacokinetic Alterations. <i>Drug Metabolism and Disposition</i> , 2022, 50, 492-499.	1.7	5
191	Relationship between Dietary Fatty Acid Intake with Nonalcoholic Fatty Liver Disease and Liver Fibrosis in People with HIV. <i>Nutrients</i> , 2021, 13, 3462.	1.7	7
192	Controlled Attenuation Parameter (CAP) with the XL Probe of the Fibroscan [®] : A Comparative Study with the M Probe and Liver Biopsy. <i>Digestive Diseases and Sciences</i> , 2017, 62, 2569-2577.	1.1	79
193	A prospective cohort study of the use of the fatty liver index and Fibroscan to determine the prevalence of fatty liver disease in an Irish population. <i>European Journal of Gastroenterology and Hepatology</i> , 2022, 34, 200-205.	0.8	2
194	Factors Affecting the Accuracy of Controlled Attenuation Parameter (CAP) in Assessing Hepatic Steatosis in Patients with Chronic Liver Disease. <i>PLoS ONE</i> , 2014, 9, e98689.	1.1	33
195	Association between the Fatty Liver Index and Risk of Type 2 Diabetes in the EPIC-Potsdam Study. <i>PLoS ONE</i> , 2015, 10, e0124749.	1.1	54
196	Association of Circulating Serum miR-34a and miR-122 with Dyslipidemia among Patients with Non-Alcoholic Fatty Liver Disease. <i>PLoS ONE</i> , 2016, 11, e0153497.	1.1	110
197	Stereological Analysis of Liver Biopsy Histology Sections as a Reference Standard for Validating Non-Invasive Liver Fat Fraction Measurements by MRI. <i>PLoS ONE</i> , 2016, 11, e0160789.	1.1	20
198	A prospective comparative assessment of the accuracy of the FibroScan in evaluating liver steatosis. <i>PLoS ONE</i> , 2017, 12, e0182784.	1.1	36
199	The relationship between visceral obesity and hepatic steatosis measured by controlled attenuation parameter. <i>PLoS ONE</i> , 2017, 12, e0187066.	1.1	24
200	Noninvasive Quantitative Detection Methods of Liver Fat Content in Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical and Translational Hepatology</i> , 2018, 6, 217-221.	0.7	38
201	Non-Invasive Assessment of Non-Alcoholic Fatty Liver Disease: Ultrasound and Transient Elastography. <i>Reviews on Recent Clinical Trials</i> , 2015, 9, 170-177.	0.4	12
202	Chasing after novel non-invasive markers to identify advanced fibrosis in NAFLD. <i>Clinical and Molecular Hepatology</i> , 2013, 19, 255.	4.5	3

#	ARTICLE	IF	CITATIONS
203	KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease. <i>Clinical and Molecular Hepatology</i> , 2013, 19, 325.	4.5	105
204	Application of transient elastography in nonalcoholic fatty liver disease. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 128-141.	4.5	70
205	Controlled attenuation parameter for evaluating liver steatosis in chronic viral hepatitis. <i>World Journal of Gastroenterology</i> , 2014, 20, 6626.	1.4	37
206	Diagnostic value of controlled attenuation parameter for liver steatosis in patients with chronic hepatitis B. <i>World Journal of Gastroenterology</i> , 2014, 20, 10585.	1.4	17
207	Transient elastography: Kill two birds with one stone?. <i>World Journal of Hepatology</i> , 2013, 5, 264.	0.8	77
208	Non-invasive methods for the diagnosis of nonalcoholic fatty liver disease. <i>World Journal of Hepatology</i> , 2015, 7, 638.	0.8	68
209	Usefulness of the Controlled Attenuation Parameter for Detecting Liver Steatosis in Health Checkup Examinees. <i>Gut and Liver</i> , 2015, 9, 405-10.	1.4	10
210	Relationship between Controlled Attenuation Parameter and Hepatic Steatosis as Assessed by Ultrasound in Alcoholic or Nonalcoholic Fatty Liver Disease. <i>Gut and Liver</i> , 2016, 10, 295.	1.4	14
211	Hepatopathy Associated With Type 1 Diabetes: Distinguishing Non-alcoholic Fatty Liver Disease From Glycogenic Hepatopathy. <i>Frontiers in Pharmacology</i> , 2021, 12, 768576.	1.6	14
212	The liver steatosis severity and lipid characteristics in primary biliary cholangitis. <i>BMC Gastroenterology</i> , 2021, 21, 395.	0.8	12
213	Pioglitazone for the Treatment of Metabolic-Associated Fatty Liver Disease in People Living With HIV and Prediabetes. <i>Cureus</i> , 2021, 13, e19046.	0.2	4
214	The Diagnosis of Nonalcoholic Fatty Liver Disease. <i>Korean Journal of Medicine</i> , 2014, 86, 405.	0.1	1
216	Evaluation of multiparametric echography in diagnosis of nonalcoholic fatty liver disease in type 2 diabetes mellitus. <i>Clinical Endocrinology and Endocrine Surgery</i> , 2017, .	0.1	0
217	Elastography in the Diagnosis of Non-Alcoholic Fatty Liver Disease. <i>Vestnik Rossiiskoi Akademii Meditsinskikh Nauk</i> , 2019, 74, 5-13.	0.2	3
218	Prevalence of fatty liver disease in patients with inflammatory bowel disease: a transient elastography study on the basis of a controlled attenuation parameter. <i>Marmara Medical Journal</i> , 2019, 32, 68-70.	0.2	4
219	De-novo nonalcoholic fatty liver disease at 5 years after liver transplantation: prevalence and predictive factors. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, 399-406.	0.8	7
220	The diagnostic conundrum in non-alcoholic fatty liver disease. <i>Exploration of Medicine</i> , 2020, 1, .	1.5	6
222	Steatosis Assessment with Controlled Attenuation Parameter (CAP) in Various Diseases. , 2020, , 441-457.		0

#	ARTICLE	IF	CITATIONS
223	Steatosis Assessment by Controlled Attenuation Parameter (CAP ₂), 2020, , 413-439.		0
224	Non-invasive Assessment of Non-alcoholic Fatty Liver Disease: Ultrasound and Transient Elastography. , 2020, , 115-139.		1
225	Correlation of the grade of hepatic steatosis between controlled attenuation parameter and ultrasound in patients with fatty liver: a multi-center retrospective cohort study. Korean Journal of Internal Medicine, 2020, 35, 1346-1353.	0.7	3
226	Diagnostic Assessment of Nonalcoholic Fatty Liver Disease. Korean Journal of Medicine, 2020, 95, 299-307.	0.1	0
227	Transient Elastography and Controlled Attenuation Parameter for Diagnosing Liver Fibrosis and Steatosis in Ontario: An Economic Analysis. Ontario Health Technology Assessment Series, 2015, 15, 1-58.	3.0	5
228	Controlled attenuation parameter for assessment of hepatic steatosis grades: a diagnostic meta-analysis. International Journal of Clinical and Experimental Medicine, 2015, 8, 17654-63.	1.3	40
229	Overview of Updated Practice Guidelines for Pediatric Nonalcoholic Fatty Liver Disease. Gastroenterology and Hepatology, 2018, 14, 407-414.	0.2	8
230	Fatty Liver Index for Predicting Nonalcoholic Fatty Liver Disease in an Asymptomatic Korean Population. Diagnostics, 2021, 11, 2233.	1.3	18
231	Novel screening model of obstructive sleep apnea for snorers with suspected NAFLD undergoing liver sonography. BMC Pulmonary Medicine, 2021, 21, 387.	0.8	0
232	Physical activity and diet quality in relation to non-alcoholic fatty liver disease: A cross-sectional study in a representative sample of U.S. adults using NHANES 2017-2018.. Preventive Medicine, 2022, 154, 106903.	1.6	21
233	A Potential Role for Bile Acid Signaling in Celiac Disease-Associated Fatty Liver. Metabolites, 2022, 12, 130.	1.3	2
234	Quantitative Evaluation of Hepatic Steatosis Using Advanced Imaging Techniques: Focusing on New Quantitative Ultrasound Techniques. Korean Journal of Radiology, 2022, 23, 13.	1.5	18
235	Quantitative ultrasound, elastography, and machine learning for assessment of steatosis, inflammation, and fibrosis in chronic liver disease. PLoS ONE, 2022, 17, e0262291.	1.1	19
236	Hipogonad erkeklerde non-alkolik yağlı karaciğer hastaları ve fibroscan verileri. Kahramanmaraş Sıhhiye Fakültesi Dergisi, 0, , .	0.1	0
237	Association between bedtime at night and nonalcoholic fatty liver disease diagnosed by liver ultrasound transient elastography. Diabetes Research and Clinical Practice, 2022, 184, 109195.	1.1	6
238	Severe Hepatic Steatosis Is Associated With Low-Level Viremia and Advanced Fibrosis in Patients With Chronic Hepatitis B in North America. , 2022, 1, 106-116.		1
239	Diagnostic Modalities of Non-Alcoholic Fatty Liver Disease: From Biochemical Biomarkers to Multi-Omics Non-Invasive Approaches. Diagnostics, 2022, 12, 407.	1.3	22
240	Association Between Non-invasive Diagnostic Methods of Liver Fibrosis and Type 2 Diabetes in Pediatric Patients With Non-alcoholic Fatty Liver Disease. Frontiers in Pediatrics, 2022, 10, 825141.	0.9	3

#	ARTICLE	IF	CITATIONS
241	An Open-Label Exploratory Clinical Trial Evaluating the Effects of GLS (Coptidis Rhizoma-Evodiae) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 7 Evidence-based Complementary and Alternative Medicine, 2022, 2022, 1-11.	0.5	3
242	Effect of Ramadan fasting on hepatic steatosis as quantified by controlled attenuation parameter (CAP): a prospective observational study. Egyptian Liver Journal, 2022, 12, .	0.3	5
243	A new visual quantitative assessment of ultrasound attenuation parameters for the mild liver steatosis. Annals of Translational Medicine, 2022, 10, 343-343.	0.7	0
244	Liver Ultrasound Attenuation. Ultrasound Quarterly, 2022, Publish Ahead of Print, .	0.3	4
245	The association between Helicobacter pylori with nonalcoholic fatty liver disease assessed by controlled attenuation parameter and other metabolic factors. PLoS ONE, 2021, 16, e0260994.	1.1	7
252	Correlation between Transient Elastography (Fibroscan [®]) and Ultrasonographic and Computed Tomographic Grading in Pediatric Nonalcoholic Steatohepatitis. Pediatric Gastroenterology, Hepatology and Nutrition, 2022, 25, 240.	0.4	4
253	Population-specific cut-off points of fatty liver index: a study based on the National Health and Nutrition Examination Survey data. BMC Gastroenterology, 2022, 22, .	0.8	3
254	Two-dimensional Shear-Wave Elastography and US Attenuation Imaging for Nonalcoholic Steatohepatitis Diagnosis: A Cross-sectional, Multicenter Study. Radiology, 2022, 305, 118-126.	3.6	20
255	Dietary fatty acids and risk of non-alcoholic steatohepatitis: A national study in the United States. Frontiers in Nutrition, 0, 9, .	1.6	1
256	The prevalence of alcoholic and nonalcoholic fatty liver disease in adolescents and young adults in the United States: analysis of the NHANES database. BMC Gastroenterology, 2022, 22, .	0.8	10
257	Simultaneously Screening for Liver Steatosis and Fibrosis in Romanian Type 2 Diabetes Mellitus Patients Using Vibration-Controlled Transient Elastography with Controlled Attenuation Parameter. Diagnostics, 2022, 12, 1753.	1.3	4
258	Work-up for Incidentally Detected NAFLD: How Far is It Worth?. Euroasian Journal of Hepato-gastroenterology, 2022, 12, S26-S36.	0.1	0
259	Diagnostik: Leberfettquantifizierung. , 2022, , 137-148.		0
260	The association between serum vitamin A and NAFLD among US adults varied in different BMI groups: a cross-sectional study. Food and Function, 2023, 14, 836-844.	2.1	1
261	Speed of sound index for liver steatosis estimation: a reliability study in normal subjects. , 2022, 28, 418-427.		0
262	HCV infection characteristics, treatment uptake and outcomes in patient with diabetes mellitus. BMC Endocrine Disorders, 2022, 22, .	0.9	1
263	Ultrasound-Based Diagnostic Methods: Possible Use in Fatty Liver Disease Area. Diagnostics, 2022, 12, 2822.	1.3	1
264	Practical Diagnosis and Staging of Nonalcoholic Fatty Liver Disease: A Narrative Review. European Medical Journal (Chelmsford, England), 0, , 108-118.	3.0	9

#	ARTICLE	IF	CITATIONS
265	Non-Invasive Imaging Modalities in Nonalcoholic Fatty Liver Disease: Where Do We Stand?. European Medical Journal Hepatology, 0, , 80-85.	1.0	0
266	Noninvasive Imaging Modalities in Nonalcoholic Fatty Liver Disease: Where Do We Stand?. European Medical Journal (Chelmsford, England), 0, , 57-62.	3.0	2
267	Controlled attenuation parameter-insulin resistance (CIR) score to predict non-alcoholic steatohepatitis. Scientific Reports, 2022, 12, .	1.6	1
268	Screening for MAFLD: who, when and how?. Therapeutic Advances in Endocrinology and Metabolism, 2023, 14, 204201882211456.	1.4	5
269	Circulating levels of endotrophin and cross-linked type III collagen reflect liver fibrosis in people with HIV. BMC Infectious Diseases, 2023, 23, .	1.3	0
270	Noninvasive Tests Used in Risk Stratification of Patients with Nonalcoholic Fatty Liver Disease. Clinics in Liver Disease, 2023, 27, 373-395.	1.0	3
271	Adipose Tissue, Metabolic Syndrome, and Non-Alcoholic Fatty Liver Disease – A Short Review. European Medical Journal Hepatology, 0, , 62-70.	1.0	2
272	Metabolic-Associated Fatty Liver Disease and Diabetes. Endocrinology and Metabolism Clinics of North America, 2023, 52, 469-484.	1.2	3
273	Serum Cardiotrophin-1 Concentration Is Negatively Associated with Controlled Attenuation Parameters in Subjects with Non-Alcoholic Fatty Liver Disease. Journal of Clinical Medicine, 2023, 12, 2741.	1.0	0
276	Vibration-Controlled Transient Elastography and Controlled Attenuation Parameter for Staging Nonalcoholic Fatty Liver Disease. , 2023, , 107-122.		0